Interestingly, knockout of ICAM1 (KO-ICAM1) with CRISPR technology (Supplementary Fig. 6a, b) in lung cancer cells (i.e., A549, H1299, and CL1-0) ultimately diminished the potentiation effects of DAC for γδ T cell killing in all three cell lines tested (Fig. 3e, f). Here, ICAM1 is linked to lung cancer.